Fair Value Measurements - Narrative (Details) - USD ($) $ in Thousands		3 Months Ended
	Jun. 22, 2023	Mar. 31, 2026
CVR liability
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Increase in fair value of derivative		$ 30,270
Spyre Therapeutics, Inc.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Asset acquisition, stockholder payment period (in years)	3 years
Asset acquisition, cash payment, threshold period (in years)	1 year